Pharmacogenetics Driving Personalized Medicine: Analysis of Genetic Polymorphisms in FCGR2A (Rs1801274) And ERBB2 (Rs1136201) Related to Breast Cancer Medications in Iraqis Populations

Abstract

Background:Breast-cancer is the most common cancer in women characterized by a high-variable-clinical-outcome among individuals-treated with equivalent-regimens and novel-targeted-therapies.We investigated associations between FCGR2A(rs1801274)andERBB2(rs1136201)polymorphism and clinical-outcomes in Arab and Kurdish population of Iraqi-breast-cancer-patients withHER2-negative-breast-cancer,and in women withHER2-positive-breast-cancer who received-trastuzumab.Methods:FCGR2A(rs1801274)andERBB2(rs1136201)polymorphism determined byARMS-PCRassay in-160Arab andKurdish population of Iraqi-breast-cancer-patients withHER2-negative-breast-cancer,and in women withHER2-positive breast-cancer who received-trastuzumab.Results:FCGR2Ars1801274 andERBB2(rs1136201)genotype frequencies didnot differ significantly between study-patients and controls.But in follow-up of 5-years,in1801274-Patients withAA-genotype may have increased response to trastuzumab and longer progression-free survival and in rs1136201-Patients withAA-genotype and breast-cancer may have an increased-response to treatment with trastuzumab.Conclusions:All these findings increased-knowledge on prevalence of specific variants related with breast-cancer-treatment-responsiveness.